ClinicalTrials.gg
CompletedNCT05304533Updated Jan 13, 2023

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

A Phase 1 interventional study of MYK-224 and Itraconazole in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • MYK-224
  • Itraconazole
  • Verapamil
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 30 kg/m\^2, inclusive
  • Healthy as determined by medical history, physical examination, vital signs, 12-lead and routine laboratory assessments
  • Adequate acoustic windows to enable accurate transthoracic echocardiographic assessment
  • (LVEF) ≥60% at screening and ≥55% prior to MYK-224 dosing

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic medical illness
  • History of dizziness and/or recurrent headaches
  • History of heart disease

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Arm 1: MYK-224

    Drug: MYK-224

  • Experimental
    Arm 2: MYK-224 + Itraconazole

    Drug: MYK-224 · Drug: Itraconazole

  • Experimental
    Arm 3: MYK-224 + Verapamil

    Drug: MYK-224 · Drug: Verapamil

Interventions

  • Specified dose on specified days

    Also known as: BMS-986435

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 36 days

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])

    Time frame: Up to 36 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to 36 days

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 36 days

  2. Apparent terminal plasma half-life (T-HALF)

    Time frame: Up to 36 days

  3. Apparent total body clearance (CLT/F)

    Time frame: Up to 36 days

  4. Number of participants with adverse events (AEs)

    Time frame: Up to 52 days

  5. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 52 days

  6. Number of participants with adverse events leading to discontinuation

    Time frame: Up to 52 days

  7. Number of participants with vital sign abnormalities

    Time frame: Up to 52 days

  8. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 52 days

  9. Measurement of left ventricular ejection fraction (LVEF)

    Time frame: Up to 52 days

  10. Measurement of left ventricular outflow tract velocity time integral (LVOT-VTI)

    Time frame: Up to 52 days

  11. Measurement of left ventricular fractional shortening (LVFS)

    Time frame: Up to 52 days

  12. Measurement of left ventricular global longitudinal strain (LV GLS)

    Time frame: Up to 52 days

  13. Measurement of left ventricle stroke volume (LVSV)

    Time frame: Up to 52 days

  14. Number of participants with physical exam abnormalities

    Time frame: Up to 52 days

  15. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 52 days

07

Study locations

1 site
  • Local Institution - 0001
    Dallas, Texas 75247, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Nov 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
Mar 31, 2022
StartActual
Apr 21, 2022
Primary completionActual
Nov 14, 2022
CompletionActual
Nov 29, 2022
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05304533
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Apr 21, 2022
Primary completion
Nov 14, 2022
Completion
Nov 29, 2022
Last update
Jan 13, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delocamten

Start the discussion